Sareum - Specialists in Cancer Drug Discovery
Print the page Smaller text Larger text


Change of Adviser
16 March, 2015

Research & Co-Development Collaborations Update
25 February, 2015

Half-yearly Report
25 February, 2015

Further US Patent Grant for Sareum’s Kinase Inhibitors
20 January, 2015

Result of Annnual General Meeting
17 December, 2014

RSS news feed News feed
requires RSS news reader

Sareum Holdings
Last Trading 0.33
Trade Time 9:21pm
Change 0.00
Open 0.30
Day's Range 0.28 - 0.34
Volume 16623688


Sareum's small molecule drug discovery expertise is building value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies


Providing protein structure-based research services to accelerate customers’ drug discovery programmes
Developing oncology drug candidates for licensing to pharmaceutical companies


Learn more about Sareum’s pipeline of targeted small molecule drug candidates

Annual Report & Accounts 2014 can be downloaded from our Information Page

                                                                                  Website last updated on: 11-November-2014



Requires RSS news reader

Requires MS Word

Requires Adobe Acrobat Reader

site map

cookie policy

email: info (at) tel: +44 (0) 1223 497700 fax: +44 (0) 1223 497701